These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Dixit D; Yoon Y; Volino LR; Mansukhani RP Am J Health Syst Pharm; 2015 Nov; 72(22):1943-54. PubMed ID: 26541949 [TBL] [Abstract][Full Text] [Related]
3. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Packer M Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418 [No Abstract] [Full Text] [Related]
4. [Empagliflozin: current indications and aspects for daily clinical practice]. Iacoviello M; Aspromonte N G Ital Cardiol (Rome); 2023 Dec; 24(12 Suppl 3):3S-12S. PubMed ID: 38226446 [TBL] [Abstract][Full Text] [Related]
5. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES]. Scheen AJ Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450 [TBL] [Abstract][Full Text] [Related]
6. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500 [TBL] [Abstract][Full Text] [Related]
7. Introduction. Chilton R Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180 [No Abstract] [Full Text] [Related]
8. [Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes]. Røder ME; Storgaard H; Rungby J; Knop FK; Vilsbøll T Ugeskr Laeger; 2016 Sep; 178(38):. PubMed ID: 27649712 [TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory potential of Empagliflozin. Pirklbauer M Inflammopharmacology; 2021 Apr; 29(2):573-576. PubMed ID: 33728540 [No Abstract] [Full Text] [Related]
10. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632 [TBL] [Abstract][Full Text] [Related]
11. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Carlson CJ; Santamarina ML Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721 [TBL] [Abstract][Full Text] [Related]
12. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. Riggs MM; Seman LJ; Staab A; MacGregor TR; Gillespie W; Gastonguay MR; Woerle HJ; Macha S Br J Clin Pharmacol; 2014 Dec; 78(6):1407-18. PubMed ID: 24964723 [TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Siamashvili M; Davis SN Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350 [TBL] [Abstract][Full Text] [Related]
14. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients. Babar M; Hussain M; Ahmad M; Akhtar L J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526 [TBL] [Abstract][Full Text] [Related]
15. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC; Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430 [TBL] [Abstract][Full Text] [Related]
16. [SGLT2-inhibitors (gliflozins) - multipurpose medications and the statins of the 21st century?]. Zeeh J MMW Fortschr Med; 2023 Aug; 165(14):46-48. PubMed ID: 37537462 [No Abstract] [Full Text] [Related]
18. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Liakos A; Karagiannis T; Athanasiadou E; Sarigianni M; Mainou M; Papatheodorou K; Bekiari E; Tsapas A Diabetes Obes Metab; 2014 Oct; 16(10):984-93. PubMed ID: 24766495 [TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus. Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772 [TBL] [Abstract][Full Text] [Related]
20. Empagliflozin for the treatment of type 2 diabetes. Jahagirdar V; Barnett AH Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]